Published in Semin Cell Dev Biol on July 06, 2007
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol (2009) 3.55
Open access chemical and clinical probes to support drug discovery. Nat Chem Biol (2009) 2.28
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res (2010) 1.38
Hydrogen peroxide activated matrix metalloproteinase inhibitors: a prodrug approach. Angew Chem Int Ed Engl (2010) 1.29
Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer. Oncotarget (2014) 1.28
Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab (2011) 1.27
Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol Genet Metab (2009) 1.25
Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov (2009) 1.21
ETS-1 protein regulates vascular endothelial growth factor-induced matrix metalloproteinase-9 and matrix metalloproteinase-13 expression in human ovarian carcinoma cell line SKOV-3. J Biol Chem (2012) 1.19
Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol (2015) 1.14
Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity. J Am Chem Soc (2013) 1.10
Distinct functions for the catalytic and hemopexin domains of a Drosophila matrix metalloproteinase. Proc Natl Acad Sci U S A (2009) 1.09
New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies. Biochem Res Int (2010) 1.07
New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol (2012) 1.05
Oncogenic KIT-containing exosomes increase gastrointestinal stromal tumor cell invasion. Proc Natl Acad Sci U S A (2013) 1.04
Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS (2012) 1.03
ADAM-10 and -17 regulate endometriotic cell migration via concerted ligand and receptor shedding feedback on kinase signaling. Proc Natl Acad Sci U S A (2013) 1.02
Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int J Exp Pathol (2008) 1.02
Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol (2010) 1.02
Mesotrypsin promotes malignant growth of breast cancer cells through shedding of CD109. Breast Cancer Res Treat (2009) 1.00
Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis. Ann Rheum Dis (2009) 1.00
Attacking the multi-tiered proteolytic pathology of COPD: new insights from basic and translational studies. Pharmacol Ther (2008) 0.99
Osteopontin-stimulated expression of matrix metalloproteinase-9 causes cardiomyopathy in the mdx model of Duchenne muscular dystrophy. J Immunol (2011) 0.98
Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem (2012) 0.97
The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer. Int J Mol Sci (2012) 0.96
Intestine-Derived Matrix Metalloproteinase-8 Is a Critical Mediator of Polymicrobial Peritonitis. Crit Care Med (2016) 0.94
PRSS3/mesotrypsin is a therapeutic target for metastatic prostate cancer. Mol Cancer Res (2012) 0.93
Propentofylline decreases tumor growth in a rodent model of glioblastoma multiforme by a direct mechanism on microglia. Neuro Oncol (2011) 0.93
The case for open-access chemical biology. A strategy for pre-competitive medicinal chemistry to promote drug discovery. EMBO Rep (2009) 0.93
Enzymatic activation of a matrix metalloproteinase inhibitor. Chem Commun (Camb) (2010) 0.91
Gelatinase-stimuli strategy enhances the tumor delivery and therapeutic efficacy of docetaxel-loaded poly(ethylene glycol)-poly(ɛ-caprolactone) nanoparticles. Int J Nanomedicine (2012) 0.90
A delicate balance: role of MMP-9 in brain development and pathophysiology of neurodevelopmental disorders. Front Cell Neurosci (2015) 0.90
Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res (2015) 0.90
Hydroxyproline-containing collagen analogs trigger the release and activation of collagen-sequestered proMMP-2 by competition with prodomain-derived peptide P33-42. Fibrogenesis Tissue Repair (2011) 0.89
EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol (2009) 0.88
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets (2013) 0.87
Activation of sulfonate ester based matrix metalloproteinase proinhibitors by hydrogen peroxide. J Biol Inorg Chem (2010) 0.85
PEGylation extends circulation half-life while preserving in vitro and in vivo activity of tissue inhibitor of metalloproteinases-1 (TIMP-1). PLoS One (2012) 0.85
Host matrix metalloproteinases in cerebral malaria: new kids on the block against blood-brain barrier integrity? Fluids Barriers CNS (2014) 0.84
Impact of proteolytic enzymes in colorectal cancer development and progression. World J Gastroenterol (2014) 0.83
Matrix metalloproteinase 8 (collagenase 2) induces the expression of interleukins 6 and 8 in breast cancer cells. J Biol Chem (2013) 0.83
Characterization of selective exosite-binding inhibitors of matrix metalloproteinase 13 that prevent articular cartilage degradation in vitro. J Med Chem (2014) 0.82
MMP9 is protective against lethal inflammatory mass lesions in the mouse colon. Dis Model Mech (2010) 0.81
Prevention of Abdominal Aortic Aneurysm Progression by Targeted Inhibition of Matrix Metalloproteinase Activity With Batimastat-Loaded Nanoparticles. Circ Res (2015) 0.80
RalB regulates contractility-driven cancer dissemination upon TGFβ stimulation via the RhoGEF GEF-H1. Sci Rep (2015) 0.80
Discovery of a Series of Thiazole Derivatives as Novel Inhibitors of Metastatic Cancer Cell Migration and Invasion. ACS Med Chem Lett (2013) 0.79
Melanoma cell therapy: Endothelial progenitor cells as shuttle of the MMP12 uPAR-degrading enzyme. Oncotarget (2014) 0.79
Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice. Breast Cancer Res (2015) 0.77
An integrated computational approach to rationalize the activity of non-zinc-binding MMP-2 inhibitors. PLoS One (2012) 0.77
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression. J Control Release (2017) 0.77
Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy. Front Cell Dev Biol (2014) 0.76
Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis. Oncotarget (2016) 0.75
Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction. BMC Vet Res (2016) 0.75
Inhibition of Matrix Metalloproteinase 9 Enhances Rod Survival in the S334ter-line3 Retinitis Pigmentosa Model. PLoS One (2016) 0.75
Inhibition of Breast Cancer Metastasis by Presurgical Treatment with an Oral Matrix Metalloproteinase Inhibitor: A Preclinical Proof-of-Principle Study. Mol Cancer Ther (2016) 0.75
Novel yeast bioassay for high-throughput screening of matrix metalloproteinase inhibitors. Appl Environ Microbiol (2011) 0.75
Clonal cooperativity in heterogenous cancers. Semin Cell Dev Biol (2016) 0.75
Role of matrix metalloproteinase-8 as a mediator of injury in intestinal ischemia and reperfusion. FASEB J (2016) 0.75
Proteolysis-a characteristic of tumor-initiating cells in murine metastatic breast cancer. Oncotarget (2016) 0.75
Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection. Int J Nanomedicine (2016) 0.75
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem (2017) 0.75
Biochemical and spectroscopic characterization of the catalytic domain of MMP16 (cdMMP16). J Biol Inorg Chem (2016) 0.75
Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Prog Mol Biol Transl Sci (2017) 0.75
Post-transcriptional Regulation of MMP16 and TIMP2 Expression via miR-382, miR-410 and miR-200b in Endometrial Cancer. Cancer Genomics Proteomics (2017) 0.75
New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer (2002) 24.71
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol (2000) 13.29
Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 12.29
MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell (1998) 9.70
Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 8.19
MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell (2000) 8.00
Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev (2006) 7.92
MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell (1999) 6.40
Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science (1999) 4.91
Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest (2000) 4.90
Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med (1999) 4.85
Matrix metalloproteinases: role in arthritis. Front Biosci (2006) 4.52
Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res (1998) 4.39
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J Cell Biol (2004) 4.16
An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest (2004) 4.03
Human and mouse proteases: a comparative genomic approach. Nat Rev Genet (2003) 4.02
A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res (1998) 3.77
Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science (2000) 3.75
Altered endochondral bone development in matrix metalloproteinase 13-deficient mice. Development (2004) 3.45
Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol Rev (2005) 3.30
Critical roles for collagenase-3 (Mmp13) in development of growth plate cartilage and in endochondral ossification. Proc Natl Acad Sci U S A (2004) 3.27
Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov (2007) 3.14
Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab (2000) 3.04
Decreased allergic lung inflammatory cell egression and increased susceptibility to asphyxiation in MMP2-deficiency. Nat Immunol (2002) 2.83
Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet (2003) 2.69
HIV-induced metalloproteinase processing of the chemokine stromal cell derived factor-1 causes neurodegeneration. Nat Neurosci (2003) 2.66
Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol Ther (2003) 2.61
Enamelysin (matrix metalloproteinase 20)-deficient mice display an amelogenesis imperfecta phenotype. J Biol Chem (2002) 2.59
Closure of the blood-brain barrier by matrix metalloproteinase inhibition reduces rtPA-mediated mortality in cerebral ischemia with delayed reperfusion. Stroke (2003) 2.49
Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest (2000) 2.39
Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia (2005) 2.25
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol (2004) 2.23
Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer (2006) 2.20
Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell (1997) 2.16
The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev (2007) 2.07
Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol (2001) 2.06
Activity-based probes for the proteomic profiling of metalloproteases. Proc Natl Acad Sci U S A (2004) 1.98
Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res (2002) 1.98
Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther (2006) 1.97
Matrix metalloproteinases: roles in cancer and metastasis. Front Biosci (2006) 1.96
Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice. J Clin Invest (2005) 1.94
Matrix metalloproteases in aberrant fibrotic tissue remodeling. Proc Am Thorac Soc (2006) 1.89
Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol (1998) 1.87
Matrix metalloproteinases as valid clinical targets. Curr Pharm Des (2007) 1.76
Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol (2000) 1.71
Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis (1999) 1.70
The metalloproteinase matrilysin is preferentially expressed by epithelial cells in a tissue-restricted pattern in the mouse. Mol Biol Cell (1995) 1.60
Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth. Hum Mol Genet (2007) 1.56
Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease. PLoS Med (2006) 1.54
Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease. Inflamm Res (2005) 1.50
Coordinate expression of matrix metalloproteinase family members in the uterus of normal, matrilysin-deficient, and stromelysin-1-deficient mice. Endocrinology (1997) 1.50
Matrix metalloproteinase-3-dependent generation of a macrophage chemoattractant in a model of herniated disc resorption. J Clin Invest (2000) 1.49
The design of inhibitors for medicinally relevant metalloproteins. ChemMedChem (2007) 1.44
Macrophage elastase (matrix metalloproteinase-12) suppresses growth of lung metastases. Cancer Res (2006) 1.41
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res (2006) 1.40
Positive selection on MMP3 regulation has shaped heart disease risk. Curr Biol (2004) 1.39
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev (2003) 1.38
MMP induction and inhibition in myocardial infarction. Heart Fail Rev (2004) 1.35
Deficiency of gelatinase a suppresses smooth muscle cell invasion and development of experimental intimal hyperplasia. Circulation (2003) 1.35
A protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res (2004) 1.32
Proteinase systems and thoracic aortic aneurysm progression. J Surg Res (2007) 1.32
The acute respiratory distress syndrome: fibrosis in the fast lane. Thorax (1998) 1.29
Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects. Expert Opin Ther Targets (2003) 1.27
MMP-2 null mice exhibit an early onset and severe experimental autoimmune encephalomyelitis due to an increase in MMP-9 expression and activity. FASEB J (2004) 1.26
Analysis of host- and tumor-derived proteinases using a custom dual species microarray reveals a protective role for stromal matrix metalloproteinase-12 in non-small cell lung cancer. Cancer Res (2006) 1.26
Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum (2003) 1.26
Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol (2004) 1.23
Matrix metalloproteinase knockout studies and the potential use of matrix metalloproteinase inhibitors in the rheumatic diseases. Curr Drug Targets Inflamm Allergy (2005) 1.22
Pharmacologic suppression of experimental abdominal aortic aneurysms: acomparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg (1998) 1.21
Epidermal development and wound healing in matrix metalloproteinase 13-deficient mice. J Invest Dermatol (2006) 1.18
The role of matrix metalloproteinases (MMPs) in the pathophysiology of chronic obstructive pulmonary disease (COPD): a therapeutic role for inhibitors of MMPs? Inflamm Res (2003) 1.16
Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients. Oncology (2005) 1.15
Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. Am J Clin Oncol (2002) 1.15
Matrix metalloproteinases: contribution to pathogenesis, diagnosis, surveillance and treatment of abdominal aortic aneurysms. Curr Med Res Opin (2004) 1.14
Doxycycline and other tetracyclines in the treatment of bone metastasis. Anticancer Drugs (2003) 1.13
Rupture of the atherosclerotic plaque: does a good animal model exist? Arterioscler Thromb Vasc Biol (2003) 1.11
Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation (1999) 1.09
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol (2005) 1.05
Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer (1998) 1.05
What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res (2006) 1.03
HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg (2005) 1.01
Structure-based design and synthesis of novel non-zinc chelating MMP-12 inhibitors. Bioorg Med Chem Lett (2005) 1.00
Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res (2001) 0.99
Pathogenic role of matrix metalloproteases and their inhibitors in asthma and chronic obstructive pulmonary disease and therapeutic relevance of matrix metalloproteases inhibitors. Cell Mol Biol (Noisy-le-grand) (2003) 0.98
Human macrophage metalloelastase gene expression in colorectal carcinoma and its clinicopathologic significance. Cancer (2001) 0.97
Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritis. Arthritis Res Ther (2004) 0.97
Chemically modified tetracyclines as inhibitors of matrix metalloproteinases. Drug Resist Updat (2004) 0.97
Expression of human macrophage metalloelastase gene in hepatocellular carcinoma: correlation with angiostatin generation and its clinical significance. Hepatology (1998) 0.96
Metalloproteinase inhibition prevents acute respiratory distress syndrome. J Surg Res (2001) 0.93
Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun (2004) 0.92
Large animal models of congestive heart failure: a critical step in translating basic observations into clinical applications. J Nucl Cardiol (2003) 0.90
A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res (2006) 0.90
A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer. Clin Cancer Res (2004) 0.89
General and specific host responses to bacterial infection in Peyer's patches: a role for stromelysin-1 (matrix metalloproteinase-3) during Salmonella enterica infection. Mol Microbiol (2007) 0.88
Metalloproteinase inhibition reduces constrictive arterial remodeling after balloon angioplasty: a study in the atherosclerotic Yucatan micropig. Circulation (2000) 0.88
Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD). Curr Med Res Opin (2005) 0.87
Matrix metalloproteinases in the pathogenesis of asthma and COPD: implications for therapy. Treat Respir Med (2004) 0.86